Trade KalVista Pharmaceuticals, Inc. - KALV CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | 0.06 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026235% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.004012% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Kalvista Pharmaceuticals Inc ESG Risk Ratings
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 8.38 |
| Open* | 8.66 |
| 1-Year Change* | 60.97% |
| Day's Range* | 8.61 - 8.92 |
| 52 wk Range | 4.96-11.45 |
| Average Volume (10 days) | 333.61K |
| Average Volume (3 months) | 6.30M |
| Market Cap | 265.94M |
| P/E Ratio | -100.00K |
| Shares Outstanding | 34.40M |
| Revenue | N/A |
| EPS | -3.16 |
| Dividend (Yield %) | N/A |
| Beta | 0.86 |
| Next Earnings Date | Dec 6, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 1, 2023 | 8.79 | 0.44 | 5.27% | 8.35 | 8.93 | 8.35 |
| Nov 30, 2023 | 8.38 | 0.05 | 0.60% | 8.33 | 8.59 | 8.17 |
| Nov 29, 2023 | 8.36 | 0.07 | 0.84% | 8.29 | 8.79 | 8.28 |
| Nov 28, 2023 | 8.33 | 0.45 | 5.71% | 7.88 | 8.52 | 7.74 |
| Nov 27, 2023 | 8.04 | 0.10 | 1.26% | 7.94 | 8.08 | 7.79 |
| Nov 24, 2023 | 7.96 | 0.55 | 7.42% | 7.41 | 8.11 | 7.40 |
| Nov 22, 2023 | 7.54 | -0.09 | -1.18% | 7.63 | 7.80 | 7.41 |
| Nov 21, 2023 | 7.70 | -0.28 | -3.51% | 7.98 | 8.26 | 7.63 |
| Nov 20, 2023 | 8.17 | 0.27 | 3.42% | 7.90 | 8.45 | 7.88 |
| Nov 17, 2023 | 8.10 | 0.52 | 6.86% | 7.58 | 8.11 | 7.58 |
| Nov 16, 2023 | 7.59 | -0.10 | -1.30% | 7.69 | 7.71 | 7.45 |
| Nov 15, 2023 | 7.67 | 0.03 | 0.39% | 7.64 | 8.11 | 7.61 |
| Nov 14, 2023 | 7.74 | 0.15 | 1.98% | 7.59 | 8.06 | 7.59 |
| Nov 13, 2023 | 7.69 | -0.50 | -6.11% | 8.19 | 8.19 | 7.18 |
| Nov 10, 2023 | 8.03 | 0.25 | 3.21% | 7.78 | 8.09 | 7.73 |
| Nov 9, 2023 | 7.80 | -0.52 | -6.25% | 8.32 | 8.36 | 7.65 |
| Nov 8, 2023 | 8.23 | 0.00 | 0.00% | 8.23 | 8.37 | 8.08 |
| Nov 7, 2023 | 8.32 | -0.01 | -0.12% | 8.33 | 8.58 | 8.08 |
| Nov 6, 2023 | 8.47 | -0.16 | -1.85% | 8.63 | 8.63 | 8.36 |
| Nov 3, 2023 | 8.62 | 0.02 | 0.23% | 8.60 | 8.82 | 8.48 |
KalVista Pharmaceuticals, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Wednesday, December 6, 2023 | ||
| Time (UTC) 13:30 | Country US
| Event Q2 2024 Kalvista Pharmaceuticals Inc Earnings Release Q2 2024 Kalvista Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
| Thursday, March 7, 2024 | ||
| Time (UTC) 13:30 | Country US
| Event Q3 2024 Kalvista Pharmaceuticals Inc Earnings Release Q3 2024 Kalvista Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 12.69 | 16.127 |
| Revenue | 0 | 0 | 0 | 12.69 | 16.127 |
| Total Operating Expense | 110.871 | 96.613 | 57.923 | 53.223 | 45.947 |
| Selling/General/Admin. Expenses, Total | 30.595 | 26.446 | 16.637 | 13.029 | 10.926 |
| Research & Development | 80.276 | 70.167 | 41.286 | 40.194 | 35.021 |
| Operating Income | -110.871 | -96.613 | -57.923 | -40.533 | -29.82 |
| Interest Income (Expense), Net Non-Operating | 2.183 | 0.153 | 1.95 | 1.763 | 1.498 |
| Other, Net | 15.781 | 14.121 | 9.729 | 9.53 | 7.63 |
| Net Income Before Taxes | -92.907 | -82.339 | -46.244 | -29.24 | -20.692 |
| Net Income After Taxes | -92.907 | -82.339 | -46.244 | -29.116 | -20.816 |
| Net Income Before Extra. Items | -92.907 | -82.339 | -46.244 | -29.116 | -20.816 |
| Net Income | -92.907 | -82.339 | -46.244 | -29.116 | -20.816 |
| Income Available to Common Excl. Extra. Items | -92.907 | -82.339 | -46.244 | -29.116 | -20.816 |
| Income Available to Common Incl. Extra. Items | -92.907 | -82.339 | -46.244 | -29.116 | -20.816 |
| Diluted Net Income | -92.907 | -82.339 | -46.244 | -29.116 | -20.816 |
| Diluted Weighted Average Shares | 27.8909 | 24.4731 | 19.0944 | 17.7487 | 15.0809 |
| Diluted EPS Excluding Extraordinary Items | -3.33109 | -3.36447 | -2.42186 | -1.64046 | -1.38029 |
| Diluted Normalized EPS | -3.33109 | -3.36447 | -2.42186 | -1.64046 | -1.38029 |
| Dividends per Share - Common Stock Primary Issue |
| Jul 2023 | Apr 2023 | Jan 2023 | Oct 2022 | Jul 2022 | |
|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 |
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Total Operating Expense | 29.093 | 31.728 | 26.945 | 25.883 | 26.316 |
| Selling/General/Admin. Expenses, Total | 9.786 | 7.777 | 6.882 | 7.806 | 8.13 |
| Research & Development | 19.307 | 23.951 | 20.063 | 18.077 | 18.186 |
| Operating Income | -29.093 | -31.728 | -26.945 | -25.883 | -26.316 |
| Interest Income (Expense), Net Non-Operating | 1.379 | 1.135 | 1.329 | 0.132 | -0.275 |
| Other, Net | 2.397 | 4.288 | 4.313 | 3.494 | 3.549 |
| Net Income Before Taxes | -25.317 | -26.305 | -21.303 | -22.257 | -23.042 |
| Net Income After Taxes | -25.317 | -26.305 | -21.303 | -22.257 | -23.042 |
| Net Income Before Extra. Items | -25.317 | -26.305 | -21.303 | -22.257 | -23.042 |
| Net Income | -25.317 | -26.305 | -21.303 | -22.257 | -23.042 |
| Income Available to Common Excl. Extra. Items | -25.317 | -26.305 | -21.303 | -22.257 | -23.042 |
| Income Available to Common Incl. Extra. Items | -25.317 | -26.305 | -21.303 | -22.257 | -23.042 |
| Diluted Net Income | -25.317 | -26.305 | -21.303 | -22.257 | -23.042 |
| Diluted Weighted Average Shares | 34.4142 | 34.1323 | 28.2785 | 24.595 | 24.5576 |
| Diluted EPS Excluding Extraordinary Items | -0.73566 | -0.77068 | -0.75333 | -0.90494 | -0.93828 |
| Diluted Normalized EPS | -0.73566 | -0.77068 | -0.75333 | -0.90494 | -0.93828 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 |
- Annual
- Quarterly
| 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|
| Total Current Assets | 172.326 | 193.647 | 264.264 | 88.696 | 115.546 |
| Cash and Short Term Investments | 149.375 | 166.202 | 248.929 | 67.714 | 100.811 |
| Cash & Equivalents | 56.238 | 30.732 | 50.592 | 15.789 | 32.006 |
| Total Receivables, Net | 18.644 | 14.098 | 10.418 | 16.527 | 11.315 |
| Prepaid Expenses | 4.307 | 13.347 | 4.917 | 4.455 | 3.42 |
| Total Assets | 183.202 | 203.88 | 272.013 | 92.529 | 118.132 |
| Property/Plant/Equipment, Total - Net | 10.77 | 10.04 | 7.549 | 3.655 | 2.413 |
| Total Current Liabilities | 15.032 | 11.576 | 9.774 | 7.72 | 18.052 |
| Accounts Payable | 4.817 | 3.638 | 1.981 | 1.677 | 2.86 |
| Accrued Expenses | 10.215 | 7.938 | 7.793 | 6.043 | 5.593 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0 | 9.545 | |||
| Total Liabilities | 22.177 | 18.787 | 14.82 | 8.777 | 21.394 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 161.025 | 185.093 | 257.193 | 83.752 | 96.738 |
| Redeemable Preferred Stock | |||||
| Common Stock | 0.034 | 0.025 | 0.024 | 0.018 | 0.017 |
| Additional Paid-In Capital | 507.133 | 439.104 | 426.437 | 207.208 | 191.123 |
| Retained Earnings (Accumulated Deficit) | -343.082 | -250.175 | -167.836 | -121.592 | -92.476 |
| Other Equity, Total | -3.06 | -3.861 | -1.432 | -1.882 | -1.926 |
| Total Liabilities & Shareholders’ Equity | 183.202 | 203.88 | 272.013 | 92.529 | 118.132 |
| Total Common Shares Outstanding | 34.1711 | 24.5508 | 24.4225 | 17.8456 | 17.2778 |
| Other Long Term Assets, Total | 0.106 | 0.193 | 0.2 | 0.178 | 0.173 |
| Current Port. of LT Debt/Capital Leases | 0.054 | ||||
| Capital Lease Obligations | 0 | ||||
| Other Liabilities, Total | 7.145 | 7.211 | 5.046 | 1.057 | 3.342 |
| Short Term Investments | 93.137 | 135.47 | 198.337 | 51.925 | 68.805 |
| Property/Plant/Equipment, Total - Gross | 13.728 | 12.459 | 9.638 | 5.023 | 3.309 |
| Accumulated Depreciation, Total | -2.958 | -2.419 | -2.089 | -1.368 | -0.896 |
| Jul 2023 | Apr 2023 | Jan 2023 | Oct 2022 | Jul 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 149.842 | 172.326 | 192.133 | 151.216 | 170.407 |
| Cash and Short Term Investments | 123.257 | 149.375 | 171.685 | 122.273 | 142.075 |
| Cash & Equivalents | 49.409 | 56.238 | 85.049 | 38.585 | 37.863 |
| Short Term Investments | 73.848 | 93.137 | 86.636 | 83.688 | 104.212 |
| Total Receivables, Net | 20.57 | 18.644 | 12.681 | 21.93 | 19.289 |
| Prepaid Expenses | 6.015 | 4.307 | 7.767 | 7.013 | 9.043 |
| Total Assets | 160.332 | 183.202 | 203.468 | 162.838 | 182.319 |
| Property/Plant/Equipment, Total - Net | 10.384 | 10.77 | 11.138 | 11.425 | 11.694 |
| Other Long Term Assets, Total | 0.106 | 0.106 | 0.197 | 0.197 | 0.218 |
| Total Current Liabilities | 14.132 | 15.032 | 11.606 | 11.32 | 9.733 |
| Accounts Payable | 5.06 | 4.817 | 1.698 | 3.384 | 2.908 |
| Accrued Expenses | 9.072 | 10.215 | 9.908 | 7.936 | 6.825 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 20.997 | 22.177 | 19.027 | 19.025 | 17.747 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 6.865 | 7.145 | 7.421 | 7.705 | 8.014 |
| Total Equity | 139.335 | 161.025 | 184.441 | 143.813 | 164.572 |
| Common Stock | 0.034 | 0.034 | 0.034 | 0.025 | 0.025 |
| Additional Paid-In Capital | 510.591 | 507.133 | 504.725 | 444.588 | 441.914 |
| Retained Earnings (Accumulated Deficit) | -368.399 | -343.082 | -316.777 | -295.474 | -273.217 |
| Other Equity, Total | -2.891 | -3.06 | -3.541 | -5.326 | -4.15 |
| Total Liabilities & Shareholders’ Equity | 160.332 | 183.202 | 203.468 | 162.838 | 182.319 |
| Total Common Shares Outstanding | 34.2666 | 34.1711 | 34.1278 | 24.602 | 24.5709 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -82.339 | -46.244 | -29.116 | -20.816 | -15.805 |
| Cash From Operating Activities | -78.134 | -30.171 | -44.816 | -36.365 | 10.558 |
| Cash From Operating Activities | 0.564 | 0.537 | 0.512 | 0.378 | 0.18 |
| Non-Cash Items | 15.963 | 7.19 | 4.428 | 2.863 | 0.409 |
| Cash Interest Paid | |||||
| Changes in Working Capital | -12.322 | 8.346 | -20.64 | -18.79 | 25.774 |
| Cash From Investing Activities | 57.86 | -147.654 | 16.753 | -69.422 | -1.427 |
| Capital Expenditures | -0.931 | -0.082 | -0.22 | -1.081 | -1.427 |
| Other Investing Cash Flow Items, Total | 58.791 | -147.572 | 16.973 | -68.341 | 0 |
| Cash From Financing Activities | 1.581 | 212.117 | 11.584 | 87.943 | 8.986 |
| Issuance (Retirement) of Stock, Net | 1.581 | 212.117 | 11.638 | 88.152 | 9.137 |
| Foreign Exchange Effects | -1.167 | 0.511 | 0.262 | -1.205 | 1.988 |
| Net Change in Cash | -19.86 | 34.803 | -16.217 | -19.049 | 20.105 |
| Issuance (Retirement) of Debt, Net | 0 | -0.054 | -0.209 | -0.151 |
| Jan 2023 | Oct 2022 | Jul 2022 | Apr 2022 | Jan 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -66.602 | -45.299 | -23.042 | -82.339 | -58.226 |
| Cash From Operating Activities | -52.625 | -43.336 | -22.742 | -78.134 | -51.345 |
| Cash From Operating Activities | 0.53 | 0.331 | 0.158 | 0.564 | 0.408 |
| Non-Cash Items | 7.168 | 5.214 | 3.498 | 15.963 | 11.66 |
| Changes in Working Capital | 6.279 | -3.582 | -3.356 | -12.322 | -5.187 |
| Cash From Investing Activities | 47.625 | 50.142 | 30.044 | 57.86 | 45.426 |
| Capital Expenditures | -1.127 | -1.112 | -0.92 | -0.931 | -0.845 |
| Other Investing Cash Flow Items, Total | 48.752 | 51.254 | 30.964 | 58.791 | 46.271 |
| Cash From Financing Activities | 58.149 | 0.336 | 0.168 | 1.581 | 1.443 |
| Issuance (Retirement) of Stock, Net | 58.149 | 0.336 | 0.168 | 1.581 | 1.443 |
| Foreign Exchange Effects | 1.168 | 0.711 | -0.339 | -1.167 | -0.539 |
| Net Change in Cash | 54.317 | 7.853 | 7.131 | -19.86 | -5.015 |
| Issuance (Retirement) of Debt, Net | 0 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
KalVista Pharmaceuticals, Inc. Company profile
About Kalvista Pharmaceuticals Inc
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecule protease inhibitors for diseases with unmet need. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). Plasma kallikrein is a serine protease enzyme, which is an early mediator of inflammation and edema. The body modulates the inflammatory effects of plasma kallikrein through a circulating inhibitor protein called C1-esterase inhibitor (C1-INH). The Company is primary focused on the development of the oral plasma kallikrein inhibitors for HAE. It has two drug program candidates in clinical trials. The Company’s DME program is focused on the development of an intravitreally administered small molecule plasma kallikrein inhibitor, KVD001, which completed a Phase II trial.
Financial summary
BRIEF: For the nine months ended 31 January 2022, Kalvista Pharmaceuticals Inc revenues was not reported. Net loss increased 86% to $58.2M. Higher net loss reflects Research and development increase of 73% to $51M (expense), General and administrative increase of 80% to $18.8M (expense), foriegn exchange gain/loss decrease from $715K (income) to $529K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.75 to -$2.38.
| Industry: | Biopharmaceuticals |
55 Cambridge Pkwy Ste 901E
CAMBRIDGE
MASSACHUSETTS 02142-1234
US
Income Statement
- Annual
- Quarterly
News
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023
UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?
UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.
10:48, 21 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com